Filter

141-150 of 374 results

  • This chart shows vaccination rates by country income levels.

    A Year of Vaccine Inequity

    Feature

    Just 7% of low-income countries' populations have received at least one dose of a COVID-19 vaccine as of December 20, well behind the 40% target for 2021.

  • Putting U.S. Global COVID-19 Vaccine Donations in Context

    Policy Watch

    While some have praised the most recent U.S. donation announcement as an important development, others have said the U.S. could do much more, pointing to the large supply of doses the U.S. is building up and the slowing demand for vaccinations in the country.  In this policy watch, we sought to put the U.S. pledge of 80 million doses in further context.

  • Tracking Global COVID-19 Vaccine Equity: An Update

    Issue Brief

    This updated analysis looks at global COVID-19 vaccination efforts by income-level and region to assess the equity gap in both vaccination coverage and rates of administration. Overall, we find that low-income countries and countries in Africa are lagging behind, and based on current rates, are unlikely to meet global vaccination targets.

  • Misinformation About COVID-19 Vaccines and Pregnancy is Widespread, Including Among Women Who are Pregnant or Planning to Get Pregnant

    News Release

    Misinformation and confusion about the COVID-19 vaccines and pregnancy remains widespread, with most people – including women who are pregnant or trying to get pregnant – either believing or being uncertain about at least one of three false claims they’ve heard, a new KFF COVID-19 Vaccine Monitor shows. Among women who are pregnant or trying to get pregnant – the group for whom accurate information about the vaccines’ safety before, during and after pregnancy is…

  • COVID-19 Vaccination Rates Among Children Under 5 Have Peaked and Are Decreasing Just Weeks Into Their Eligibility

    Issue Brief

    Children between the ages of 6 months and 5 years of age finally became eligible for COVID-19 vaccination in the U.S. on June 18, after the Director of the Centers for Disease Control and Prevention (CDC) recommended their use for this population, following emergency use authorization granted by the Food and Drug Administration. Here, we examine the status of vaccine uptake in this group, one month into their eligibility.

  • The COVAX Humanitarian Buffer for COVID-19 Vaccines: Review and Assessment of Policy Implications

    Issue Brief

    In this Issue Brief we review and assess the COVAX Humanitarian Buffer mechanism, which is part of the effort to share Covid vaccines globally. The Buffer is intended to direct vaccines to vulnerable people like refugees and others facing humanitarian emergencies during the pandemic, and was supported by the US and many other donors and organizations. However, it faced many challenges such as liability and indemnification issues for using newly developed vaccines, restricted access to…

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.

  • FAQs on Medicare Coverage and Costs Related to COVID-19 Testing and Treatment

    Issue Brief

    These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries, including questions related to out-of-pocket costs, the COVID-19 vaccine, telehealth, extended supplies of medication, skilled nursing facility stays, and issues for people in private Medicare Advantage plans.